TIGIT Specific NeutraTM Antibody Products
Product listT cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSIG9, is a protein expressed in peripheral blood mononuclear cells and involved in T cell apoptosis. TIGIT interacts with ligands such as CD155 and CD112 expressed by antigen-presenting cells (APCs) and tumor cells in the tumor microenvironment (TME). The inhibitors against TIGIT can attack tumors by blocking interaction with TIGIT via activation of the immune system.
Its Gene ID is 201633, UniProtKB ID is Q495A1, and OMIM ID is 612859.
Signaling Pathway & Function
As an inhibitor, TIGIT mediates strong inhibitory signaling pathways for innate and adaptive immunity, as shown in Fig.1. Here are five main inhibitory mechanisms associated with TIGIT in TEM:
- Inhibits T cell function by direct binding of CD155 on DCs with intrinsic inhibitory effect.
- Binds CD155 on APCs and inhibits T cells indirectly by regulating cytotoxin production.
- Binds CD155 on tumor cells or APCs and inhibits CD226-mediated T/NK cell activation.
- Enhances the immunosuppressive function and stability of regulatory T cells (Tregs).
- Binds Fap2 protein of Fusobacterium nucleatum and triggers inhibitory signals for T/NK cells.
Fig.1 Schematic representation of TIGIT inhibition pathways in the TME.1
Clinical Significance of TIGIT
Anti-TIGIT antibodies have become hotspots for immunotherapy. More than a dozen TIGIT antibodies are currently being developed in various stages of clinical and preclinical research (see Table 1).
The development of bispecific antibodies targeting TIGIT and another immune checkpoint protein such as PD-L1 is also in development. These bispecific antibodies could augment the therapeutic efficacy against tumors due to their high specificity and affinity for both targets, including TIGIT.
Table 1 Anti-TIGIT molecules for immunotherapy.2
Creative Biolabs offers a broad range of anti-TIGIT monoclonal antibodies. These antibodies are recombinant and undergo strict quality control.
REFERENCES
- Chauvin, Joe-Marc, and Hassane M. Zarour. "TIGIT in cancer immunotherapy." Journal for immunotherapy of cancer 8.2 (2020).
- Rotte, Anand, Srikumar Sahasranaman, and Nageshwar Budha. "Targeting TIGIT for immunotherapy of cancer: update on clinical development." Biomedicines 9.9 (2021): 1277.
